Results 51 to 60 of about 18,434 (234)

Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies

Medicina, 2023
Background and objectives: Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen deprivation therapy is indicated. The aim of this paper is to present
Carol M. MacLean, Albertas Ulys, Feliksas Jankevičius, Žilvinas Saladžinskas, Steve van Os, Finn Larsen   +5 more
doaj   +1 more source

Gonadotropin releasing hormone agonists: Expanding vistas

Indian Journal of Endocrinology and Metabolism, 2011
Gonadotropin-releasing hormone (GnRH) agonists are derived from native GnRH by amino acid substitution which yields the agonist resistant to degradation and increases its half-life. The hypogonadotropic hypogonadal state produced by GnRH agonists has been often dubbed as “pseudomenopause” or “medical oophorectomy,” which are both misnomers.
openaire   +3 more sources

The effect of ovarian stimulation protocol on follicular asynchrony during in vitro fertilization – A retrospective cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To examine the effect of controlled ovarian stimulation (COS) protocol on follicular synchrony in a subsequent in vitro fertilization (IVF) cycle in patients whose previous cycle was canceled due to asynchrony. Methods A single‐center retrospective‐cohort study (January 2018–March 2024), including women undergoing IVF who had: (1) a ...
Alyssa Hochberg, Maria Hincapie, Uri Amikam, Nir Kugelman, William Buckett, Shauna Reinblatt   +5 more
wiley   +1 more source

The Oocyte/Antral Follicle Count Index: Does Maximizing Oocyte Yield Translate into Better Assisted Reproductive Technology Outcomes?

Journal of Ultrasound in Medicine, EarlyView.
Objectives Whether aspiration of more oocytes than the antral follicle count (AFC) is beneficial for the current and future products of assisted reproductive technologies (ART) cycles. Methods Data of the first oocyte aspiration for intracytoplasmic sperm injection performed between 2018 and 2022 in attempt to conceive (ICSI, n = 399) or for planned ...
Shir Danieli‐Gruber, Onit Sapir, Dan Netanely, Avital Wertheimer, Avi Ben‐Haroush, Eran Altman, Tzippy Shochat, Yoel Shufaro   +7 more
wiley   +1 more source

Impact of an oral gonadotropin-releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained-release gonadotropin-releasing hormone agonist : A case report.

, 2021
pdfPostoperative hormone therapy for hormone-sensitive patients with breast cancer is important to prevent a recurrence. As hormone therapy does not induce infertility in patients, fertility-preserving therapy is not provided during treatment.
花田, 哲郎, 7753, KITAZAWA, Jun, 木村, 文則, 20240666, 0000-0002-9840-4227, 北澤, 純, 30823900, 60757219, 森宗, 愛菜, 564, MORIMUNE, Aina, 90322148, 0000-0002-0250-0856, MURAKAMI, Takashi, 村上, 節, 7755, 802, 7548, 0000-0001-8183-9702, KIMURA, Fuminori, HANADA, Tetsuro   +21 more
core   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Differential expression and functional characterization of luteinizing hormone receptor splice variants in human luteal cells : Implications for luteolysis

, 2009
The human LH receptor (LHR) plays a key role in luteal function and the establishment of pregnancy through its interaction with the gonadotropins LH and human chorionic gonadotropin.
Dickinson, Rachel E, Myers, Michelle, Duncan, W Colin, Stewart, Alan J., Millar, Robert P   +4 more
core   +1 more source

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection

, 1994
To evaluate the effects of treatment with the gonadotropin releasing hormone (GnRH) agonist goserelin before endometrial resection on absorption of distension medium fluid and technical feasibility of the surgical ...
F. Mauro, T. Bramante, P. G. Crosignani, L. Trespidi, P.G. Crosignani, P. Vercellini, S. Panazza   +6 more
core   +1 more source

Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells

Taiwanese Journal of Obstetrics & Gynecology, 2014
Objective: Gonadotropin-releasing hormone (GnRH) receptor is found in the ovarian tissue, including epithelial ovarian cancer (EOC), suggesting that GnRH agonists may have direct action on EOC.
Kuan-Hao Tsui, Wen-Ling Lee, Kok-Min Seow, Lin-Wei Yang, Shih-Yi Wang, Peng-Hui Wang, Chi-Lun Chang, Ming-Shyen Yen, Jiin-Tsuey Cheng, Chih-Ping Chen   +9 more
doaj   +1 more source